OrbusNeich Achieves Record-breaking Revenue, Sales Volume and Gross Profit in FY2025, Net Profit Rises to US$42 million, Final Dividend Increases by 20% to HK12 Cents per Share

Results Highlights: Revenue increased by 10.0% year-on-year to a record high of US$180.5 million, marking the fifth consecutive year of record-setting revenue performance. Sales volume hit a new high of 2.02 million units, representing a year-on-year increase of 16.2%. Gross

More

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis

HONG KONG, March 11, 2026 – (ACN Newswire via SeaPRwire.com) – March 9, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital

More